Skip To Main Content
Junta Sakakibara on Muck Rack

Junta Sakakibara

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Junta

Contact Junta, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Clinical benefit of palbociclib retreatment after abemaciclib exposure in hormone receptor positive, HER2 negative metastatic breast cancer

|
By Muhan Yu, Michiko Yamashita, Mamoru Takada, Daisuke Takabatake, Mina Takahashi, Midori Kondo, Takeshi Nagashima, Hiroshi Fujimoto, Junta Sakakibara, Ryotaro Teranaka, Kenjiro Aogi, Masayuki Otsuka, Mariko Kochi, Maya Uno
| Nature Verified
Abstract Cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) combined with endocrine therapy are standard first-line treatment for HR + /HER2– metastatic breast cancer (MBC). However, disease progression and treatment-limiting adverse events (AEs) remain major challenges, and the clinical benefit of CDK4/6i retreatment after prior exposure is uncertain.
Open in Who Shared Issue with article?

Exploring the mechanism of action of abemaciclib in breast cancer through circulating chromatin fragments

|
By Mamoru Takada, Sakuntha D. Gunarathna, Muhan Yu, Hideyuki Yamada, Takeshi Nagashima, Hiroshi Fujimoto, Junta Sakakibara, Hiroto Yamamoto, Mayumi Iida, Tsutomu Kawaguchi, Masayuki Otsuka, Motoki Takaku, Regina Nguyen, Paige Bonnet
| Nature Verified
Abstract Cell free DNA (cfDNA) analysis has a large potential for cancer patient diagnosis. Given the evidence that cfDNA partially preserves chromatin architecture of tumor cells, it potentially allows the detection of tumor responses after therapeutic treatment. This study aimed to detect the responses of abemaciclib, a selective inhibitor of cell cycle regulators CDK4 and CDK6, in metastatic recurrent breast cancer patients through cfDNA analysis.
Open in Who Shared Issue with article?
See all 2 articles